About

Medical Isotopes save lives.

Nuclear Medicine departments at hospitals and cancer treatment centres use radioisotopes for both diagnosis of disease (such as cancer & cardiovascular disease) as well as therapy for some forms of cancer.  Radioisotopes are an unstable form of an element that emits radiation to transform into a more stable form.  For therapy, the isotope is part of a drug that seeks diseased cells, typically cancers.  The radiation emitted by the isotope can then destroy the cells with considerable focus to limit other cell damage.

Copper 67 (Cu-67) is an emerging therapy medical isotope for new cancer treatments. Cu-67 is an ideal radiotherapy medical isotope similar to yttrium-90 (Y-90), iodine-131 (I-131) and lutetium-177 (Lu-177) medical isotopes that are already in use for immunology.  However, production of these other isotopes (Y-90, I-131 and Lu-177) relies on aging nuclear research reactors and processing facilities, resulting in uncertain availability and high replacement costs.

Through cutting-edge diagnostic technology, isotopes (Technetium -99m – Tc-99m) are used to identify internal ailments and allow medical professionals to quickly and accurately treat patients. Previously, the production of these medical isotopes occurred only at a small number of nuclear facilities, which created harmful waste and came with a long list of security and supply concerns.

Our goal at CIIC is the production of safe, pure medical isotopes produced in a direct and reliable manner. We are the first producer of reactor-free medical isotopes on a commercial scale, providing a solution to a worldwide shortage.

Our dependable product and supply chain allows physicians to help patients with the care they need. Through entrepreneurial innovation and advanced technology, our process is clean, safe, and renewable.